Phased AMED GRiT support · Biotech

Surv BioPharma announces up to ¥1.7 billion in AMED support

Phased support will advance an oncolytic virus programme for rare soft-tissue cancers.

Surv BioPharma announced on 1 October 2026 that AMED had selected its Surv.m-CRA-1 programme for support of up to approximately ¥1.7 billion under the GRiT initiative. The company plans to use the support to advance international Phase 2 development for rare malignant soft-tissue tumours.

The programme supports feasibility work ahead of an international trial. Support for the trial phase depends on AMED’s assessment and covers up to half of eligible costs, so the announced figure is a phased funding ceiling.

The Kagoshima University spinout is developing Surv.m-CRA-1, an engineered oncolytic virus designed to replicate selectively in cancer cells.

Use of funds

International clinical development of Surv.m-CRA-1 for rare malignant soft-tissue tumours

Funding history

Sources

  1. Surv BioPharma announces AMED GRiT support for Surv.m-CRA-1prtimes.jp · Oct 1, 2026
  2. survbiopharma.co.jp